The phase III NETTER-2 study evaluated Lu-177 dotatate as first-line treatment in patients with grade 2 and 3 advanced gastroenteropancreatic neuroendocrine tumors. Results were presented at the 2024 ASCO Gastrointestinal Cancers Symposium (Abstract LBA588).
